Cancer Clinical Trials & Research Studies Listings is a quarterly guide published for healthcare professionals. It provides a list of cancer clinical trials and research studies at the Stanford Cancer Institute. An asterisk at the end of a study title indicates that the protocol will soon open to accrual.

At the end of each listing is a series of numbers. The first number is the OnCore database number. The second number is the IRB e-protocol number.

Additional information such as eligibility requirements can be found on the following web sites: cancer.stanford.edu/trials, clinicaltrials.gov, and cancer.gov/clinicaltrials

To download our Cancer Clinical Trials Mobile Search App visit:
iTunes: itunes.apple.com/us/app/sci-trials/id944048084?mt=8
If you have questions about the App, contact: ccto-website@stanford.edu

If you or your patients have any questions or concerns or need further information, please contact the Cancer Clinical Trials Outreach Specialist at: (650) 498-7061 or ccto-office@stanford.edu.

Ofrecemos asistencia en español acerca de estudios clínicos de cáncer: (650) 724-3155

Please only distribute this publication to other healthcare professionals.
## TABLE OF CONTENTS

Contact List for Cancer Clinical Trials & Research Studies ................................................................. 1

### Clinical Trials & Research Studies

- Multiple/Variety ........................................................................................................ 4
  - Population Sciences ............................................................................................. 8
  - Breast ................................................................................................................. 8
  - Prevention and Control ....................................................................................... 8
  - Colon ................................................................................................................. 8
  - Prevention and Control ....................................................................................... 8
  - Gastrointestinal .................................................................................................. 8
  - Epidemiology ..................................................................................................... 8
  - Prevention and Control ....................................................................................... 8
  - Liver .................................................................................................................... 8
  - Prevention and Control ....................................................................................... 8
  - Lung ...................................................................................................................... 8
  - Prevention and Control ....................................................................................... 8
  - Prostate ................................................................................................................ 8
  - Prevention and Control ....................................................................................... 8
  - Bladder ................................................................................................................ 9
  - Blood and Marrow Transplant (BMT) .................................................................. 9
  - Bone ..................................................................................................................... 12
  - Brain/Nervous System ....................................................................................... 12
  - Breast ................................................................................................................. 15
  - Adjuvant Therapy ............................................................................................... 16
  - Neoadjuvant Therapy ......................................................................................... 16
  - Metastatic ........................................................................................................... 16
  - Radiation Oncology ............................................................................................ 18
  - Genetics/High Risk ............................................................................................ 18
  - Imaging Protocols ............................................................................................... 18
  - Biomarker & Molecular ...................................................................................... 19
  - Survivorship ....................................................................................................... 19
  - Endocrine ........................................................................................................... 20
  - Observational ..................................................................................................... 19
  - Gastrointestinal .................................................................................................. 20
  - Multiple Variety ................................................................................................. 20
  - Anal ...................................................................................................................... 20
  - Colon & Rectum ................................................................................................. 20
  - Gastroesophageal ............................................................................................... 21
  - Hepatobiliary ..................................................................................................... 21
  - Neuroendocrine ................................................................................................ 23
  - Pancreas ............................................................................................................. 24
  - Genomics – Molecular Targeted Therapy ........................................................... 25
  - Multiple/Variety ................................................................................................. 25
  - Gastrointestinal .................................................................................................. 26
  - Gastroesophageal ............................................................................................... 26
  - Pancreas ............................................................................................................. 26
  - Gynecologic ....................................................................................................... 26
  - Ovarian .............................................................................................................. 26
  - Germ Cell Tumors .............................................................................................. 26
  - Gynecologic ....................................................................................................... 27

- Ovarian/Peritoneal/Fallopian .................................................................................. 27
- Endometrial ........................................................................................................... 27
- Cervical .................................................................................................................. 28
- Survivorship ......................................................................................................... 28
- Head & Neck ........................................................................................................ 28
- Kidney ................................................................................................................... 30
- Leukemia .............................................................................................................. 31
- Multiple Histologies ............................................................................................. 31
- Acute Lymphoblastic Leukemia .......................................................................... 32
- Acute Myeloid Leukemia ..................................................................................... 34
- Chronic Lymphocytic Leukemia .......................................................................... 35
- Lung & Respiratory Tract .................................................................................... 36
- Lymphoma: Hodgkin’s ....................................................................................... 39
- Lymphoma: Non-Hodgkin’s .............................................................................. 40
- Follicular / Indolent B-Cell ................................................................................ 40
- Untreated .............................................................................................................. 40
- Previously Treated ............................................................................................... 40
- Diffuse Large B-Cell ............................................................................................ 40
- Untreated .............................................................................................................. 40
- Previously Treated ............................................................................................... 41
- Diagnostic .............................................................................................................. 41
- Mantle Cell ........................................................................................................... 41
- Untreated .............................................................................................................. 41
- Waldenström’s Macroglobulinemia ..................................................................... 41
- Multiple Histologies ............................................................................................. 41
- Previously Treated ............................................................................................... 41
- Peripheral T-Cell Lymphoma ............................................................................. 42
- Cutaneous T-Cell Lymphoma ............................................................................. 42
- Melanoma/Other Skin Cancers .......................................................................... 43
- Stage IV Melanoma ............................................................................................. 43
- Basal Cell Carcinoma ........................................................................................... 44
- Merkel Cell Carcinoma ......................................................................................... 44
- Multiple Myeloma ................................................................................................. 44
- Multiple Myeloma/Myelodysplastic Syndrome (MDS) ....................................... 44
- Myelodysplastic Syndrome (MDS) ..................................................................... 44
- Myeloproliferative Disorders (MPD) .................................................................. 45
- Neuroblastoma ..................................................................................................... 46
- Prostate ................................................................................................................ 47
- Quality of Life ....................................................................................................... 49
- Gastroesophageal ................................................................................................. 49
- Liver ....................................................................................................................... 49
- Prostate ................................................................................................................ 49
- Quality of Life/Cancer Survivorship ................................................................... 49
- Anal/Colon & Rectum ......................................................................................... 49
- Sarcoma ................................................................................................................ 49
- Urothelial ............................................................................................................... 51

Contact Information
- Stanford Cancer Clinical Trials Office ................................................................... 52
- Lucile Packard Children’s Hospital, Hematology/Oncology ................................. 52
- Cancer Prevention Institute of California ............................................................ 52
<table>
<thead>
<tr>
<th>NAME</th>
<th>PHONE</th>
<th>PAGER</th>
<th>EMAIL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adelman, Donna</td>
<td>724-1953</td>
<td>16790</td>
<td><a href="mailto:donna@stanford.edu">donna@stanford.edu</a></td>
</tr>
<tr>
<td>Aoki, Rhonda-Lee</td>
<td>723-0371</td>
<td></td>
<td><a href="mailto:raoki@stanford.edu">raoki@stanford.edu</a></td>
</tr>
<tr>
<td>Ahern, Maria</td>
<td>725-6413</td>
<td>17359</td>
<td><a href="mailto:mahern@stanford.edu">mahern@stanford.edu</a></td>
</tr>
<tr>
<td>Avedian, Raffi S., MD</td>
<td>721-2479</td>
<td></td>
<td><a href="mailto:ravedian@stanford.edu">ravedian@stanford.edu</a></td>
</tr>
<tr>
<td>Baggott, Christina</td>
<td>497-7659</td>
<td></td>
<td><a href="mailto:baggott@stanford.edu">baggott@stanford.edu</a></td>
</tr>
<tr>
<td>Bailey, Irene</td>
<td>721-7149</td>
<td>408-892-7261</td>
<td><a href="mailto:baileyhi@stanford.edu">baileyhi@stanford.edu</a></td>
</tr>
<tr>
<td>Baumann, Kellie</td>
<td>723-4547</td>
<td>15185</td>
<td><a href="mailto:kbaumann@stanford.edu">kbaumann@stanford.edu</a></td>
</tr>
<tr>
<td>Bertrand, Sophie</td>
<td>723-4467</td>
<td></td>
<td><a href="mailto:sophieb@stanford.edu">sophieb@stanford.edu</a></td>
</tr>
<tr>
<td>Bobo, Sally</td>
<td>736-1472</td>
<td></td>
<td><a href="mailto:sbobo@stanford.edu">sbobo@stanford.edu</a></td>
</tr>
<tr>
<td>Brown, Janice, MD</td>
<td>868-8073</td>
<td></td>
<td><a href="mailto:wesbrown@stanford.edu">wesbrown@stanford.edu</a></td>
</tr>
<tr>
<td>Brown, Katie</td>
<td>723-1423</td>
<td></td>
<td><a href="mailto:kbrown5@stanford.edu">kbrown5@stanford.edu</a></td>
</tr>
<tr>
<td>Bruce, Carol</td>
<td>804-4613</td>
<td></td>
<td><a href="mailto:cbruce@stanford.edu">cbruce@stanford.edu</a></td>
</tr>
<tr>
<td>Bui, Justin</td>
<td>498-7703</td>
<td>15267</td>
<td><a href="mailto:jlbui@stanford.edu">jlbui@stanford.edu</a></td>
</tr>
<tr>
<td>Castaneda, Annabel (Grace)</td>
<td>498-7977</td>
<td></td>
<td><a href="mailto:annabelc@stanford.edu">annabelc@stanford.edu</a></td>
</tr>
<tr>
<td>CCTO Office</td>
<td>498-7061</td>
<td></td>
<td><a href="mailto:ccto-office@stanford.edu">ccto-office@stanford.edu</a></td>
</tr>
<tr>
<td>Chang, Anne, MD</td>
<td>721-7151</td>
<td>23351</td>
<td><a href="mailto:alschang@stanford.edu">alschang@stanford.edu</a></td>
</tr>
<tr>
<td>Chang, Pei-Jen</td>
<td>725-0866</td>
<td>15665</td>
<td><a href="mailto:peijenc@stanford.edu">peijenc@stanford.edu</a></td>
</tr>
<tr>
<td>Chase, Peter</td>
<td>736-1556</td>
<td></td>
<td><a href="mailto:pwchase@stanford.edu">pwchase@stanford.edu</a></td>
</tr>
<tr>
<td>Chen, Jie Jane</td>
<td>736-0921</td>
<td>16067</td>
<td><a href="mailto:jjchen15@stanford.edu">jjchen15@stanford.edu</a></td>
</tr>
<tr>
<td>Choudhury, Sipra, MSc, MS</td>
<td>736-2563</td>
<td></td>
<td><a href="mailto:schoudhury@stanford.edu">schoudhury@stanford.edu</a></td>
</tr>
<tr>
<td>Chua, Mei-Sze, PhD</td>
<td>724-3525</td>
<td></td>
<td><a href="mailto:mchua@stanford.edu">mchua@stanford.edu</a></td>
</tr>
<tr>
<td>Daniels, Cristina</td>
<td>723-0381</td>
<td></td>
<td><a href="mailto:crisdan7@stanford.edu">crisdan7@stanford.edu</a></td>
</tr>
<tr>
<td>Dauniac, Jennifer</td>
<td>736-0697</td>
<td></td>
<td><a href="mailto:jdauniac@stanford.edu">jdauniac@stanford.edu</a></td>
</tr>
<tr>
<td>Di Bari, Chuck</td>
<td>498-4073</td>
<td></td>
<td><a href="mailto:cdibaril@stanford.edu">cdibaril@stanford.edu</a></td>
</tr>
<tr>
<td>Dib, Ekaterina</td>
<td>723 0503</td>
<td></td>
<td><a href="mailto:ekatdib@stanford.edu">ekatdib@stanford.edu</a></td>
</tr>
<tr>
<td>Estevez, Nini, MPH, CCRC</td>
<td>725-4041</td>
<td>17312</td>
<td><a href="mailto:nestevez@stanford.edu">nestevez@stanford.edu</a></td>
</tr>
<tr>
<td>Falwell, Alyson, MPH</td>
<td>736-4281</td>
<td></td>
<td><a href="mailto:Falwell@stanford.edu">Falwell@stanford.edu</a></td>
</tr>
<tr>
<td>Fisher, George A., Jr., MD, PhD</td>
<td>725-9057</td>
<td>13786</td>
<td><a href="mailto:georgef@stanford.edu">georgef@stanford.edu</a></td>
</tr>
<tr>
<td>Freiberg, Rachel</td>
<td>725-4777</td>
<td></td>
<td><a href="mailto:rachelf@stanford.edu">rachelf@stanford.edu</a></td>
</tr>
<tr>
<td>Friedrich, Suzanne</td>
<td>725-0426</td>
<td>17103</td>
<td><a href="mailto:suzf@stanford.edu">suzf@stanford.edu</a></td>
</tr>
<tr>
<td>Gable, Laura</td>
<td>736-0798</td>
<td>17605</td>
<td><a href="mailto:laurawl1@stanford.edu">laurawl1@stanford.edu</a></td>
</tr>
<tr>
<td>Gallant, Pamela</td>
<td>736-8965</td>
<td></td>
<td><a href="mailto:pamela6@stanford.edu">pamela6@stanford.edu</a></td>
</tr>
<tr>
<td>Galvez, Leah, RN</td>
<td>725-7951</td>
<td></td>
<td><a href="mailto:lsgalvez@stanford.edu">lsgalvez@stanford.edu</a></td>
</tr>
<tr>
<td>Gambhir, Sam, MD, PhD</td>
<td>725-2309</td>
<td></td>
<td><a href="mailto:sgambhir@stanford.edu">sgambhir@stanford.edu</a></td>
</tr>
<tr>
<td>Ganjoo, Kristen, MD</td>
<td>725-6413</td>
<td>13212</td>
<td><a href="mailto:kganjoo@stanford.edu">kganjoo@stanford.edu</a></td>
</tr>
<tr>
<td>Gonzalez, Alma, MPH</td>
<td>498-0624</td>
<td></td>
<td><a href="mailto:alma.gonzalez@stanford.edu">alma.gonzalez@stanford.edu</a></td>
</tr>
<tr>
<td>Haas, Denise, MBA, CCRP</td>
<td>736-1252</td>
<td>15653</td>
<td><a href="mailto:dhaas@stanford.edu">dhaas@stanford.edu</a></td>
</tr>
<tr>
<td>Name</td>
<td>Phone Number</td>
<td>Email Address</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>Hao, Ying</td>
<td>723-0646</td>
<td><a href="mailto:yhao@stanford.edu">yhao@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Hansmann, Leo, MD</td>
<td>723-7218</td>
<td><a href="mailto:leo2@stanford.edu">leo2@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Hanapowicz, Tessa</td>
<td>721-4096</td>
<td><a href="mailto:tkhar@stanford.edu">tkhar@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Hasan, Alifia</td>
<td>721-4088</td>
<td><a href="mailto:alifia@stanford.edu">alifia@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Hegde, Priya</td>
<td>723-0920</td>
<td><a href="mailto:phegde@stanford.edu">phegde@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Hiniker, Susan, MD</td>
<td>12425</td>
<td><a href="mailto:shinker@stanford.edu">shinker@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Lagraru, Andrei, MD</td>
<td>736-2859</td>
<td><a href="mailto:aialagraru@stanford.edu">aialagraru@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Isaacsom, Amy, MSW, CCRC</td>
<td>723-0501</td>
<td><a href="mailto:amy@stanford.edu">amy@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Iv, Michael</td>
<td>723-4527</td>
<td><a href="mailto:mviv@stanford.edu">mviv@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Jain, Vani</td>
<td>723-1005</td>
<td><a href="mailto:vani@stanford.edu">vani@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Jalali, Moe</td>
<td>724-4023</td>
<td><a href="mailto:moej@stanford.edu">moej@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Jeffrey, Stefanie, MD</td>
<td>723-0799</td>
<td><a href="mailto:ssj@stanford.edu">ssj@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Jiron, Risa, BA, BS, CCRC</td>
<td>736-1598</td>
<td><a href="mailto:jjiron@stanford.edu">jjiron@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Kale, Aarti</td>
<td>723-0622</td>
<td><a href="mailto:aarkle@stanford.edu">aarkle@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Kamaya, Aya, MD</td>
<td>723-8463</td>
<td><a href="mailto:kamayau@stanford.edu">kamayau@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Kamble, Savita</td>
<td>723-8594</td>
<td><a href="mailto:skamble@stanford.edu">skamble@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Kasson, Rachel</td>
<td>723-0168</td>
<td><a href="mailto:rkasson@stanford.edu">rkasson@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Khan, Asma</td>
<td>724-6008</td>
<td><a href="mailto:asmak@stanford.edu">asmak@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Kothapalli, Raj, PhD</td>
<td>725-3113</td>
<td><a href="mailto:kraj@stanford.edu">kraj@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Krampitz, Geoffrey, MD</td>
<td>497-8000</td>
<td><a href="mailto:krampitz@stanford.edu">krampitz@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Kumar, Prianka</td>
<td>724-3866</td>
<td><a href="mailto:prianak@stanford.edu">prianak@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Lau, Karen</td>
<td>723-0658</td>
<td><a href="mailto:kkwau@stanford.edu">kkwau@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Lien, Leilani, BSN, RN, PHN</td>
<td>725-0437</td>
<td><a href="mailto:hilien11@stanford.edu">hilien11@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>May, Mary (Tookie)</td>
<td>721-4079</td>
<td><a href="mailto:mmay2@stanford.edu">mmay2@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>McDonald, Kathleen</td>
<td>725-8589</td>
<td><a href="mailto:kmcdonald@stanford.edu">kmcdonald@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>McDowell, Janet</td>
<td>725-1647</td>
<td><a href="mailto:janetm2@stanford.edu">janetm2@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>McGlennen, Kristine, RN</td>
<td>723-3589</td>
<td><a href="mailto:kmcglen@stanford.edu">kmcglen@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Medeiroso, Bruno, MD</td>
<td>723-5007</td>
<td><a href="mailto:brunom@stanford.edu">brunom@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Melcher, Marc, MD, PhD</td>
<td>498-5688</td>
<td><a href="mailto:melcherm@stanford.edu">melcherm@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Mendoza, Hordeliza, CCRC</td>
<td>724-2056</td>
<td><a href="mailto:floromendo@stanford.edu">floromendo@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Metzner, Tommy</td>
<td>723-0766</td>
<td><a href="mailto:tmetzner@stanford.edu">tmetzner@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Meyer, Shannon</td>
<td>724-1953</td>
<td><a href="mailto:smeyeron@stanford.edu">smeyeron@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Mills, Meredith</td>
<td>724-5223</td>
<td><a href="mailto:bluett@stanford.edu">bluett@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Monge-Deisseroth, Michelle, MD, PhD</td>
<td>725-5459</td>
<td><a href="mailto:mmonge@stanford.edu">mmonge@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Morrison, Kevin</td>
<td>725-7061</td>
<td><a href="mailto:kmorrison@stanford.edu">kmorrison@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Nair, Viswan, MD</td>
<td>725-0912</td>
<td><a href="mailto:vbk@stanford.edu">vbk@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Naseem, Kashif</td>
<td>736-8729</td>
<td><a href="mailto:kashif@stanford.edu">kashif@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Nouriani, Bita</td>
<td>723-8479</td>
<td><a href="mailto:bital@stanford.edu">bital@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Okada, Ami, PhD</td>
<td>725-4968</td>
<td><a href="mailto:amo@stanford.edu">amo@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Otani, Joanne, RN, MSN</td>
<td>721-2372</td>
<td><a href="mailto:joanne.otani@stanford.edu">joanne.otani@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Packer, Melissa</td>
<td>723-6250</td>
<td><a href="mailto:mpacker2@stanford.edu">mpacker2@stanford.edu</a></td>
<td></td>
</tr>
<tr>
<td>Pan, Janet</td>
<td>723-0628</td>
<td><a href="mailto:janetpan@stanford.edu">janetpan@stanford.edu</a></td>
<td></td>
</tr>
</tbody>
</table>

**Pediatrics**

<table>
<thead>
<tr>
<th>Name</th>
<th>Phone Number</th>
<th>Email Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pham, Phuong</td>
<td>725-9810</td>
<td><a href="mailto:pppham5@stanford.edu">pppham5@stanford.edu</a></td>
</tr>
<tr>
<td>Physician Referrals</td>
<td>723-0822</td>
<td></td>
</tr>
<tr>
<td>Phahn, Caitlin</td>
<td>723-3046</td>
<td><a href="mailto:cphahn@stanford.edu">cphahn@stanford.edu</a></td>
</tr>
<tr>
<td>Poushejed, Shermeen</td>
<td>724-7662</td>
<td><a href="mailto:shermeen@stanford.edu">shermeen@stanford.edu</a></td>
</tr>
<tr>
<td>Powell, Ashley, PhD</td>
<td>724-3308</td>
<td><a href="mailto:ashley.powell@stanford.edu">ashley.powell@stanford.edu</a></td>
</tr>
<tr>
<td>Pradhan, Pooja</td>
<td>725-4099</td>
<td><a href="mailto:pooja1@stanford.edu">pooja1@stanford.edu</a></td>
</tr>
<tr>
<td>Priestley, Benjamin, MPH, CCRC</td>
<td>723-2990</td>
<td><a href="mailto:ben.priestley@stanford.edu">ben.priestley@stanford.edu</a></td>
</tr>
<tr>
<td>Quick, Richard</td>
<td>723-2983</td>
<td><a href="mailto:richardq@stanford.edu">richardq@stanford.edu</a></td>
</tr>
<tr>
<td>Rai, Smriti</td>
<td>723-0270</td>
<td><a href="mailto:smriti@stanford.edu">smriti@stanford.edu</a></td>
</tr>
<tr>
<td>Rajapaksa, Amanda</td>
<td>723-0546</td>
<td><a href="mailto:amandar1@stanford.edu">amandar1@stanford.edu</a></td>
</tr>
<tr>
<td>Rajanasi, Illilaa</td>
<td>412-1397</td>
<td><a href="mailto:illilaa@stanford.edu">illilaa@stanford.edu</a></td>
</tr>
<tr>
<td>Recht, Cathy, RN, MS</td>
<td>723-6095</td>
<td><a href="mailto:crecht@stanford.edu">crecht@stanford.edu</a></td>
</tr>
<tr>
<td>Reddy, Sunil Arani, MD</td>
<td>736-1234</td>
<td><a href="mailto:sreddy@stanford.edu">sreddy@stanford.edu</a></td>
</tr>
<tr>
<td>Rockweiler, Holly</td>
<td>916-905-6586</td>
<td><a href="mailto:hrock@stanford.edu">hrock@stanford.edu</a></td>
</tr>
<tr>
<td>Rooney, Diane</td>
<td>725-8474</td>
<td><a href="mailto:drooney@stanford.edu">drooney@stanford.edu</a></td>
</tr>
<tr>
<td>Sable, Jean</td>
<td>723-0530</td>
<td><a href="mailto:jsable@stanford.edu">jsable@stanford.edu</a></td>
</tr>
<tr>
<td>Saini, Gopin</td>
<td>725-9032</td>
<td><a href="mailto:sainig@stanford.edu">sainig@stanford.edu</a></td>
</tr>
<tr>
<td>San Pedro-Salcedo, Melanie</td>
<td>724-1388</td>
<td><a href="mailto:mspase@stanford.edu">mspase@stanford.edu</a></td>
</tr>
<tr>
<td>Shinn, Leigh, RN, BSN, CCRC</td>
<td>724-9179</td>
<td><a href="mailto:leighs@stanford.edu">leighs@stanford.edu</a></td>
</tr>
<tr>
<td>Shura, Lei</td>
<td>723-2312</td>
<td><a href="mailto:lshura@stanford.edu">lshura@stanford.edu</a></td>
</tr>
<tr>
<td>Simmons, Amanda L.</td>
<td>724-4606</td>
<td><a href="mailto:amandal@stanford.edu">amandal@stanford.edu</a></td>
</tr>
<tr>
<td>Slamovitz, Deborah, RN, BSN</td>
<td>723-2804</td>
<td><a href="mailto:dsloan@stanford.edu">dsloan@stanford.edu</a></td>
</tr>
<tr>
<td>Sonn, Geoffrey, MD</td>
<td>725-5544</td>
<td><a href="mailto:gsonn@stanford.edu">gsonn@stanford.edu</a></td>
</tr>
<tr>
<td>Sood, Sumita</td>
<td>723-0618</td>
<td><a href="mailto:ssood@stanford.edu">ssood@stanford.edu</a></td>
</tr>
<tr>
<td>Spiegel, David, MD</td>
<td>723-6421</td>
<td><a href="mailto:dspiegel@stanford.edu">dspiegel@stanford.edu</a></td>
</tr>
<tr>
<td>Subramanian, Aruna, MD</td>
<td>497-3492</td>
<td><a href="mailto:asubram2@stanford.edu">asubram2@stanford.edu</a></td>
</tr>
<tr>
<td>Sze, Daniel, MD</td>
<td>725-5202</td>
<td><a href="mailto:danz@stanford.edu">danz@stanford.edu</a></td>
</tr>
<tr>
<td>Taw, Jack</td>
<td>723-2781</td>
<td><a href="mailto:jtaw@stanford.edu">jtaw@stanford.edu</a></td>
</tr>
<tr>
<td>Tsung, Kangla, PhD</td>
<td>725-8198</td>
<td><a href="mailto:tsungk@stanford.edu">tsungk@stanford.edu</a></td>
</tr>
<tr>
<td>Ullah, Nighat</td>
<td>721-4076</td>
<td><a href="mailto:nullah@stanford.edu">nullah@stanford.edu</a></td>
</tr>
<tr>
<td>Ungewickel, Alexander, MD, PhD</td>
<td>725-6432</td>
<td><a href="mailto:anewickel@stanford.edu">anewickel@stanford.edu</a></td>
</tr>
<tr>
<td>Walters, Kelsey</td>
<td>725-6432</td>
<td><a href="mailto:kelswalters@stanford.edu">kelswalters@stanford.edu</a></td>
</tr>
<tr>
<td>Wapnir, Irvine, MD</td>
<td>736-1353</td>
<td><a href="mailto:wapnir@stanford.edu">wapnir@stanford.edu</a></td>
</tr>
<tr>
<td>Williams, Donna, RN</td>
<td>498-6608</td>
<td><a href="mailto:donnacw@stanford.edu">donnacw@stanford.edu</a></td>
</tr>
<tr>
<td>Willmann, Juergen, MD</td>
<td>725-1812</td>
<td><a href="mailto:willmann@stanford.edu">willmann@stanford.edu</a></td>
</tr>
<tr>
<td>Worman, Melissa, MPH</td>
<td>725-0379</td>
<td><a href="mailto:mlworman@stanford.edu">mlworman@stanford.edu</a></td>
</tr>
<tr>
<td>Xing, Lei, PhD</td>
<td>498-7896</td>
<td><a href="mailto:lei@stanford.edu">lei@stanford.edu</a></td>
</tr>
<tr>
<td>Young, Polly</td>
<td>497-7499</td>
<td><a href="mailto:polly14@stanford.edu">polly14@stanford.edu</a></td>
</tr>
<tr>
<td>Zhou, Lisa, PhD</td>
<td>736-4112</td>
<td><a href="mailto:yaya@stanford.edu">yaya@stanford.edu</a></td>
</tr>
</tbody>
</table>
A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors [COGABTR0181 792]

A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias [COGADVLI0921 22417]

A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors [COGADVLI1322 34202]

Key Adverse Events after Childhood Cancer [COGALTE03N1 95083]

Study of Biomarkers Indicative of Radiation Exposure [VAR0060 18793]

Umbrella Long-Term Follow-Up Protocol [COGALTE05N1 19263]

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors * [VAR0082 24778]

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy [VAR0006 13535]

Identification of Key Blood Molecular Markers for Immunotherapy * [VAR0017 5617]

A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities [VAR0095 26667]

Combined F18 and F18 FDG PET/CT for Evaluation of Malignancy [VAR0024 9434]

US Elastography for Characterizing Focal Lesions in the Liver and Kidney [VAR0099 27746]

Imaging and Biomarkers of Hypoxia in Solid Tumors [VAR0032 15039]

A Novel Therapy for Radiation-induced Xerostomia Using Human Salivary Stem Cells [VAR0050 17757]

Cardiac MRI to Monitor Patients Receiving Potentially Cardiotoxic Chemotherapies * [VAR0101 27619]

An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in Pediatric and Young Adult Patients with Previously Treated Solid Tumors * [PEDSVAR0039]

A Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung and Head and Neck Cancer * [VAR0093 26203]

A Phase I/II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias [COGACCRN07 12800]

A Phase I Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer * [VAR0088 25310]

A Phase II Study of IPILIMUMAB (ipilimumab) in Combination with Local Radiation or MPDL3280A in Melanoma, Non-Hodgkin Lymphoma and Colorectal Carcinoma * [VAR0100 28451]

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A in Melanoma, Non-Hodgkin Lymphoma and Colorectal Carcinoma * [VAR0101 27619]

A Novel Therapy for Radiation-induced Xerostomia Using Human Salivary Stem Cells [VAR0050 17757]

Cardiac MRI to Monitor Patients Receiving Potentially Cardiotoxic Chemotherapies * [VAR0101 27619]

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobin in Subjects with Advanced Solid Tumors [VAR0105 30053]
• A Phase 1b, Open-Label, Multicenter Study of Urelumab (BMS-663513) in Combination with Cetuximab in Subjects with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck * [VAR0106 30043]

• Phase 2 Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors [VAR0107 30307]

• A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors [VAR0108 29796]

• Pilot Study to Determine Concentration of Breath-Borne Volatile Compounds in Patients with Gastrointestinal and Thoracic Cancers [VAR0110 30135]

• A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies [VAR0112 30945]

• A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients with Advanced Solid Malignancies [VAR0113 31088]

• 18F FPPRGD2 PET/CT Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis [VARIMG0002 25970]

• Pilot Study of the Optimization of Gene Expression Biomarkers and Bioassay for Radiation Biodosimetry using Human Blood Irradiation Experiments to Study Gene Expression Changes following Radiation Exposure [VAR0116 31894]

• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract [VAR0117 31685]

• A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract [VAR0118 31869]

• A Phase 1, Open-label, Dose-escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors or Renal Cell Carcinoma [VAR0120 33184]

• Phase Ib Study of Intratumoral Injections of Ipilimumab Followed by Either Local Radiation or MPDL3280A in Solid Tumors * [VAR0124 33221]

• A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma [VAR0126 34636]

• A Multi-Center Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors * [VAR0127 34711]

• A Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 antibody (Varililumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors * [VAR0132 35484]

• Feasibility of Manipulator Assisted 4D Ultrasound for Soft Tissue Image Guidance in Radiation Therapy [VARIMG0003 26615]

• Comparison of 18F FDG PET/CT vs. 18F FDG PET/MRI [VARIMG0004 27398]

• An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy [VARIMG0006 31855]
<table>
<thead>
<tr>
<th>POPULATION SCIENCES</th>
<th>CONTACT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Prevention and Control</strong></td>
<td>Mills</td>
</tr>
<tr>
<td>Genetic &amp; Pathological Studies of BRCA1/BRCA2: Associated Tumors &amp; Blood Samples [BRSNSTU0020 11872]</td>
<td>Mills</td>
</tr>
</tbody>
</table>

| Colon              |         |
| **Prevention and Control** | Mills |
| Molecular Genetic and Pathological Studies of Colorectal Tumors and Blood Samples [COR0005 11886] | Mills |

| Gastrointestinal Epidemiology |         |
| **Prevention and Control** | Mills |
| The Gastric Cancer Foundation: A Gastric Cancer Registry [GI0005 20285] | Mills |

| Liver               |         |
| **Prevention and Control** | Mills |
| Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma [HEP0006 10767] | Chua |

| Lung                |         |
| **Prevention and Control** | Zhou |
| Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients [LUN0017 4086] | Zhou |

| Prostate            |         |
| **Prevention and Control** | Haas |
| Quality of Life Following Radical Prostatectomy [PROS0012 13913] | Haas |

| BLADDER            |         |
| **Prevention and Control** | Haas |
| Optical Imaging of Bladder Cancer with Molecular Contrast Agents [BLDR0014 17425] | Metzner |

| **Prevention and Control** | Haas |
| A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (AntiPD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with PD-L1 Selected, High Risk Muscle Invasive Bladder Cancer After Cystectomy * [BLDR0017 34596] | Haas |

| **Prevention and Control** | Haas |
| A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations * [BLDR0018 35375] | Haas |

| **Prevention and Control** | Poushnejad |
| A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer * [BLDR0019 35654] | Poushnejad |

| **Prevention and Control** | Plahn |
| A Randomized Phase II Study of Co Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer [ECOGS1314 33603] | Plahn |

| **Prevention and Control** | Brown (Katie) |
| Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer * [NRGGU001 CIRB] | Brown (Katie) |

| BLOOD AND MARROW TRANSPLANT (BMT) | Physician Referrals |
| **PREVENTION AND CONTROL** | Physician Referrals |
| Defibrotide for Hematopoietic Stem Cell Transplant (SCT) Patient with Severe Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study [BMT196 15059] | Physician Referrals |

| **PREVENTION AND CONTROL** | Physician Referrals |
| A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Patients with Cutaneous T Cell Lymphoma [BMT206 16213] | Physician Referrals |
• Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy after Non-Myeloablative Allogeneic Transplantation in Patients with Myelodysplasia or Myeloproliferative Disorders [BMT217 18127]

• Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined with Local Radiation for the Treatment of Recurrent or Progressive Lymphoma after Allogeneic Hematopoietic Cell Transplantation [BMT235 20741]

• Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T cell Depleted Graft with Simultaneous Infusion of Conventional T Cells and Regulatory T Cells [BMT236 21257]

• A Phase I Study of CD8+ Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematolymphoid Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation [BMT243 22626]

• A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies [BMT248 25803]

• A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease [BMT253 27285]

• A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) [BMT255 27477]

• A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls [BMT260 31391]

• A Phase 1 Single Center Safety and Feasibility Study of Primary T Regulatory Cell Therapy to Treat Visceral Acute Graft-Versus-Host Disease Following Hematopoietic Cell Transplantation [BMT267 30861]

• A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease [BMT268 30677]

• Chronic GVHD Response Measures Validation [BMT270 FCCRC IRB]

• A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) [BMT284 33222]

• A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation [BMT285 32842]

• Post Transplant Infusion of Allogeneic CD8 Memory T-Cells as Consolidate Therapy After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with Leukemia and Lymphoma [BMT288 33058]

• Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off-The-Shelf ex vivo Expanded Cord Blood Progenitor Cells in Patients with Hematologic Malignancies * [BMT291 External IRB 2603]

• Pilot Safety and Feasibility trial of Mycophenolate and Sirolimus for Prevention of GVHD in Mismatched Unrelated and Related Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies * [BMT295 34973]
• A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT) * [COGACCL1131 CIRB]

• Impact of Alemtuzumab on Lowering Minimal Residual Disease (MRD) in Patients with CD52+ Leukemia Undergoing Allogeneic Hematopoietic Progenitor Cell Transplant (HPCT) [PEDSMT256 27404]  

BRAIN / NERVOUS SYSTEM CONTACT

• A Phase I/II Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme [BRN0012 17774]  

• A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM [BRN0023 27845]  

• 18F FDOPA PET/CT or PET/MRI in Patients with Gliomas * [BRN0024 29364]  

• A Phase I Study of Ad-RTS-hIL-12, An Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma * [BRN0025 30275]  

• A Pilot Study Assessing Early Changes in PET/MRI After Bevacizumab Administration in Patients with Glioblastoma Multiforme [BRN0026 31114]  

• A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain Treated with Nivolumab in Combination with Ipilimumab Followed by Nivolumab Monotherapy [BRN0027 33114]  

• An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects with Intracranial Cancers [BRNCNS0005 30415]  

• Exploration of Activity of RAD001 in Vestibular Schwannomas and Meningiomas: An NF2 Therapeutic Development Consortium Trial * [BRNCNS0006 29797]  

• MR Imaging of Inflammatory Responses in the Central Nervous System with Ferumoxytol-enhanced MRI [BRNCNS0007 26570]  

• A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) * [NRGA071101 30098]  

• Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Patients with Brain Metastases * [NRGCC001 CIRB]  

• Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas * [RTOG1072-ECOG3F05 CIRB]  

• Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients [COGACNS0332 13130]
• Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial [COGACNS0821 20672]

• Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years [COGACNS0831 19761]

• A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas * [COGACNS1022 CIRB-ACNS1022]

• Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) [COGACNS1123 CIRB-ACNS1123]

• Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer [COGALTE07C1 15429]

• Phase II Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma * [PBTC039 29685]

• Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma [PBTC029 24860]

• A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma * [PBTC032 24929]

• Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors [PBTC042 32121]

• Phase II Study of (18F) FLT for PET Imaging of Brain Tumors in Children [PBTCN12 30620]

• Comprehensive Molecular Analysis of Tumor Samples Derived From Patients With Diffuse Brainstem Glioma - A Pilot Study [PEDSBRN0013 14785]

• Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas * [PEDSBRN0018 28789]

• Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy during Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation (Re-MATCH) * [PEDSBRNCNS0004 31054]

• A Phase II/I Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG) [PBTC033 28539]

• A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma [PEDSBRN0017 29236]

• A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) [BRS0045 31976]

• A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation * [NSABPB52 CIRB]

Neoadjuvant Therapy

• Neoadjuvant Therapy

BREAST CONTACT

Neoadjuvant Therapy

• A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) [BRS0045 31976]

• A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation * [NSABPB52 CIRB]

Neoadjuvant Therapy

• A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) [BRS0045 31976]

• A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation * [NSABPB52 CIRB]

Neoadjuvant Therapy

• A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC) [BRS0045 31976]

• A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation * [NSABPB52 CIRB]
### Metastatic

- A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH [BRS0024 25806]

- A Phase II Study of Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer [BRS0033 28181]

- A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer [BRS0043 31019]

- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer - MONARCH 2 [BRS0044 31572]

- Phase II BMN 673 in BRCA1 + BRCA2 Wild-Type Patients w/ Advanced Triple-Neg / HER2-Neg Breast Cancer [BRS0050 31913]

- Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer [BRS0054 34299]

- A Phase III Randomized, Double-Blind, Placebo-Controlled Study of LEE011 or Placebo in Combination with Tamoxifen and Goserelin or a Non-Steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women with Hormone Receptor Positive, HER2-Negative, Advanced Breast Cancer * [BRS0055 34442]

- An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors * [BRS0059]

- A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors [VAR0108 29796]

- A Phase I Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select HER2-expressing Advanced Solid Tumors * [VAR0128 35362]
- A Multicenter Phase II Clinical Trial of PM01183 in BRCA1/2–Associated or Unselected Metastatic Breast Cancer [BRSMTS0022 30087]

- A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple Negative Breast Cancer [BRSMTS0023 33813]

- A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment * [BRSMTS0024 35255]

- An Open-Label, Single-Arm, Phase II Study of Pertuzumab with High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients with HER2-Positive Metastatic Breast Cancer (PATRICIA) * [BRSMTS0025]

**Radiation Oncology**

- A Multi-Center Feasibility Study of Accelerated Partial Breast Irradiation with IORT after Lumpectomy for Breast Cancer * [BRSADJ0016 15333]

**Genetics/High Risk**

- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples [BRSNSTU0020 11872]

**Imaging Protocols**

- High Resolution 3D Diffusion-weighted Breast MRI [BRS0013 19595]

- Ultrasound Molecular Imaging of Focal Breast Lesions * [BRS0021 22842]

**Biomarker & Molecular**

- Molecular and Cellular Analysis of Breast Cancer [BRS0040 29691]

- Breast Interstitial Fluid * [BRS0060 34896]

- Immunohistochemical & Immunoblot Analysis of NIS (Na+/I- Symporter) in Archival and Frozen Human Tissue Samples [BRSNSTU0011 11005]

**Survivorship**

- Pilot Study to Investigate the Impact of Hypochlorite in the Prevention of Radiation Dermatitis [BRS0039 29833]

- Evaluation of Method to Increase Vaginal Blood Flow in Women with Symptomatic Atrophic Vaginitis - A Proof of Concept Study [BRS0041 30639]

**Observational**

- Prefrontal Cortex Abnormalities Associated with Breast Cancer Chemotherapy [BRS0002-COR]
- Determining the Utility of Tattooing Axillary Lymph Nodes Undergoing Percutaneous Biopsy for Breast Cancer Staging [BRS0026 17233]
- Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions * [BRSADJ0030 34959]

**ENDOCRINE**

- Photoacoustic Imaging of the Thyroid * [END0017 27818]
- 68Ga DOTA-TATE PET/CT in the Evaluation of Patients with Somatostatin Receptor Positive Tumors [NET0017 26988]

**GASTROINTESTINAL**

- Endoscopic Detection of Gastrointestinal Cancers Using Anti-CD47 Antibody or Recombinant High-Affinity SIRPα Variant * [GIIMG0005 33621]
- Molecular Genetic and Pathological Studies of Anal Tumors [ANAL0001 14037]
- Vaginal Quality of Life and Functional Outcomes after Combined Modality Therapy of Chemotherapy and Intensive Modulated Radiation Therapy (IMRT) for Rectal and Anal Cancer Patients [REC0005 17711]
- Molecular Genetic and Pathological Studies of Colorectal Tumors and Blood Samples [COR0005 11886]
- A Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer [COR0011 27303]
- A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects with Metastatic Colorectal Cancer [COR0012 30276]
- A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CIRB) [ECOGC80702 24191]
- A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision [ECOGN1048 24440]
- A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) * [ECOGS0820 27430]
- Vaginal Quality of Life and Functional Outcomes after Combined Modality Therapy of Chemotherapy and Intensive Modulated Radiation Therapy (IMRT) for Rectal and Anal Cancer Patients [REC0005 17711]
- Perfusion CT as a Predictor of Treatment Response in Patients with Rectal Cancer [REC0006 19224]

**Gastroesophageal**

- The Gastric Cancer Foundation: A Gastric Cancer Registry [GI0005 20285]
- A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma * [GI0012]
• Detection of Integrin Alpha v-Beta 6 in Pancreatic Cancer with [18F]-R01-MG-FZ: a First in Human Study * [GIIMG006 34376]

• A Phase 2 Pilot Study of Trametinib in Combination with Pazopanib in Patients with Metastatic or Local-Regionally Recurrent GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib * [GIST0004]

• Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma [GIUPR0001 13473]

• A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma [RTOG1010 21828]

Hepatobiliary

• Treatment of Children with All Stages of Hepatoblastoma [COGAHEP0731 18679]

• Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma [HEP0006 10767]

• Isolation of Tumor-initiating Cells from Human Hepatocellular Carcinoma [HEP0019 15580]

• An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding by Means of an Adjunctive Application of BioFoam® Surgical Matrix in Liver Surgery * [HEP0029 17480]

• Molecular Analysis of Liver Cancer * [HEP0034 16225]

• Phase 3 Prospective, Randomized, Blinded and Controlled Investigation of Hepasphere/Quadrisphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer [HEP0038 21103]

• Pilot Feasibility Study on 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Patients with Liver Metastases [HEP0043 24334]

• Development of Predictive Models of Therapeutic Response in Hepatocellular Carcinoma Utilizing a Combination of Advanced Imaging and Genomic Profiling of Excised Tumor Tissue [HEP0044 25019]

• Feasibility of Contrast-enhanced 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation * [HEP0048 30071]

• International Randomized Study of Transarterial Chemoembolization (TACE) versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma after Initial TACE * [HEP0052 31701]

• A Phase I, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors * [HEP0053]

Neuroendocrine

• A Phase II Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors [NET0012 22412]

• A Multicenter, Stratified, Open, Randomized, Comparator-Controlled, Parallel-Group Phase III Study Comparing Treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients with Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours [NET0014 22968]

• A Phase 3, Randomized, Placebo-controlled, Multicenter, Doubleblind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome [NET0018 28510]

• A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) [NET0019EXT 28519]
• A Phase 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Gastrointestinal Neuroendocrine Tumors/Carcinoid (GI-NET) with Elevated Biomarkers [NET0020 31047]

• Rollover Protocol for Subjects Who Have Responded on Study OX4218s, “A Phase 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Gastrointestinal Neuroendocrine Tumors/Carcinoid (GI-NET) with Elevated Biomarkers” * [NET0020-EXT 34408]

• Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma (pancreatic neuroendocrine cohort only) * [NET0021]

• A021202 Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) versus Placebo in Patients with Progressive Carcinoid Tumors * [ECOGA021202 30617]

• A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors [ECOGE2211 27439]

Pancreas

• A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) with or without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer [PANC0015 27492]

• A Phase 1 Pharmacokinetic and Safety Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in Combination with Carboplatin in Subjects with Advanced Solid Malignancies [PANC0017 31068]

• A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 with or without Nivolumab in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma [PANC0019 33810]

• Detection of Integrin αvβ6 in Pancreatic Cancer with [18F]-R01-MG-F2: a First in Human Study * [PANC0020 34376]

• Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients with Resectable Pancreatic or Periampullary Cancer * [PANC0021 34865]

• A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma * [PANC0022]

• A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma * [PANC0023]

• A Phase 1/2 Study of Indoximod in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas [METS0001 34133]

Tumor Genomic Profiling: A Personalized Medicine Approach [VAR0114 29525]

CONTACT

Multiple/Variety

Tumor Genomic Profiling: A Personalized Medicine Approach Mills
• My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents [VAR0115 31825]

**Gastrointestinal**

**Gastroesophageal**

• A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer * [GI0009 32372]

**Pancreas**

• A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy [PANC0018 32280]

**Gynecologic**

**Ovarian**

• Prospective Collection of Samples to Enable the Validation of Circulating DNA Biomarkers for the Early Detection of Ovarian Cancer * [GYNOVA0034 33540]

**GERM CELL TUMORS**

• Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) vs. Bleomycin, Etoposide and Cisplatin (BEP) for Patients with Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors [GCT0001 28609]

**GYNECOLOGIC CONTACT**

**Ovarian/Peritoneal/Fallopian**

• 64Cu-DOTA-B-Fab as a PET Tracer for Evaluating CA6 Expression in Tumors: a First in Human Study * [GYNOVA0033 32991]

• PM1183-C-004-14 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Plantimum-resistant Ovarian Cancer (CORAIL Trial) * [GYNOVA0035 33814]

• A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GS1120212) in Patients with Recurrent or Progressive Low-grade Serous Ovarian Cancer or Primary Peritoneal Cancer [GOG0281 CIRB]

• A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [GYNOP0011 28228]

• Ultrasound and Photoacoustic Imaging of Surgically Removed Ovarian Tissue and Fallopian Tubes * [GYNOP0013 30927]

• Transvaginal Ultrasound and Photoacoustic Imaging of the Ovaries and the Fallopian Tubes: A Clinical Feasibility Study * [GYNOP0014 31295]

• A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Women with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received at Least Three Previous Chemotherapy Regimens [GYNOP0015 33903]

**Endometrial**

• A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin /Placebo As Initial Therapy for Measurable Stage III OR IVA, Stage IVB, or Recurrent Endometrial Cancer [GOG0286B CIRB]

**CONTACT**

Pham

Kale

Friedrich

Powell

Kothapalli

Jiron

Powell

Friedrich
<table>
<thead>
<tr>
<th>Cervical</th>
<th>Survivorship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer [GYNCVX0002 23080]</td>
<td>Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer [GYNCVX0003 25821]</td>
</tr>
<tr>
<td>Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer [GYNCVX0003 25821]</td>
<td>Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy [GYN0005 29074]</td>
</tr>
</tbody>
</table>

**HEAD & NECK**

| Identification and Characterization of Novel Proteins in Head and Neck [ENT0008 11402] | Identification of Serum Markers for Tumor Hypoxia in Head and Neck Cancer [ENT0016 10564] |
| weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients with SCCHN [ENT0033 22329] | A Phase 2 Study of Sequential and Concurrent Chemoradiation for Patients with Advanced Nasopharyngeal Carcinoma (NPC) [ENT0025 15411] |
| Telomere Length and Mutations in Head and Neck Squamous Cell Cancer Patients [ENT0038 27479] | A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin’s Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer [ENT0042 32439] |
| A Pilot Study of Dabrafenib for Patients with BRAF-Mutated Ameloblastoma * [ENT0043 32275] | A Phase 2 Study of Narrow Band Imaging (NBI) to Characterize Patterns of Vascular Supply within the Lymphoepithelial Mucosa of Patients with Oropharyngeal Carcinoma (OPC) [ENT0044 32355] |

**CONTACT**

<table>
<thead>
<tr>
<th>Young</th>
<th>Young</th>
<th>Rajapaksa</th>
<th>Simmons</th>
<th>Jiron</th>
<th>Hegde</th>
<th>Jiron</th>
<th>Hegde</th>
<th>Hasan</th>
<th>Hasan</th>
<th>May</th>
<th>Young</th>
</tr>
</thead>
</table>

| A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity * [ENT0045 34500] | A Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer [ECOGE3311 28585] |
| A Phase 2 Study of TH-4000 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin * [ENT0046 35094] | Randomized Phase II and Phase III Studies of Individualized Treatment for Oropharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) [NRGHN001 CIRB] |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) * [ENT0047 34845] | A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin’s Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer [ENT0042 32439] |
| A Feasibility Study of the VibrantTM Smartphone App for Head & Neck Cancer Patients: Improving Radiation-Induced Dysphagia by Improving Adherence to Swallow Therapy [ENT0048 34387] | Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer during Surgical Procedures * [ENT0050 35064] |
| Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures * [ENT0049 35068] | Phase Ib/II Trial of IPH2201 and Cetuximab in Patients with HPV (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck * [ENT0052] |
| Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer [ECOGE3311 28585] | A Randomized Phase II and Phase III Studies of Individualized Treatment for Oropharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) [NRGHN001 CIRB] |
- A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer [NRGHN002 CIRB]
- Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck [RTOG1216 CIRB]

**KIDNEY**

- Renal Tumors Classification, Biology, and Banking Study [COGARENB03B2 9179]
- Perfusion CT in Evaluation of Renal Malignancies * [RENA0020 17575]
- Pilot Study of Local Tumor Irradiation with Autologous T-Cell Infusion for Metastatic Renal Cell Carcinoma [RENA0027 27710]
- Biomarkers for Renal Cell Carcinoma [RENA0028 26213]
- Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib vs Placebo in Subjects at High Risk of Recurrent RCC [RENA0029 29786]
- A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma [RENA0030 30117]
- A Phase II Study of Alternative Sunitinib Scheduling in Patients with Metastatic Renal Cell Carcinoma (mRCC) * [RENA0031 30393]
- A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients with Papillary Renal Cell Carcinoma (PRCC) [RENA0032 30627]
- A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma [RENA0033 32181]
- A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features [ECOG1808 19934]

**LEUKEMIA**

- A Pilot Study Using Luminex Bioassay Technology to Analyze Patterns of Protein Expression in Tissue from Patients with Hematologic Cancers and Other Hematologic Disorders [HEM0001 1996]
- An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies [HEM0015 18748]
- Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies [HEM0026 25483]
- An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil) [HEM0029-EXT 26675]
- Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality * [HEM0030 28875]
- A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [HEM0032 27361]
- A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation * [HEM0034 28257]

**CONTACT**

- Falwell
- Kamaya
- Haas
- Metzner
- Haas
- Haas
- Haas
- Haas
- Haas
A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy with Hypomethylating (HMA) Agent * [HEM0036 28524]

Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study [HEM0038 29279]

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation * [HEM0040 31090]

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [HEM0041 31543]

Feasibility of a Computerized Neurocognitive Intervention Program in the Early Post-Transplant Setting [PEDSHEM0004 31680]

A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Leukemia or Myelodysplastic Syndrome [PEDSHEM0005 34647]

A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia and Burkitt’s Leukemia) * [SWOGS1312 28993]

**Acute Lymphoblastic Leukemia**

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens [COGAALL0581 7740]

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia [COGAALL0881 20000]

Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia [COGAALL0932 20005]

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum [COGAALL1131 24001]

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy) [COGAALL1231 CIRB]

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [COGAALL1331-BMT299 CIRB]

Phase II Study of SQ Bortezomib in Combination with Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia * [HEMALL0008 25596]

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL) * [HEMALL0012 33392]

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients with Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia [PEDSHEMALL0004 31906]

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients with Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia [PEDSHEMALL0005 34792]
• A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults * [SWOGE1910 CIRB]

**Acute Myeloid Leukemia**

• A Phase 2 Study of Temozolomide Plus Vorinostat for Elderly Patients (>60) with Newly Diagnosed Acute Myeloid Leukemia (AML) or Relapse/Refractory AML * [HEMAML0017 22794]

• A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients with Acute Myelogenous Leukemia Who Are 60 Years or Older * [HEMAML0021 26194]

• A Phase II Study of Decitabine in Combination with Midostaurin (PKC412) for Elderly Patients with Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia * [HEMAML0022 25737]

• A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) * [HEMAML0024 27313]

• A Phase II Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) with Mutated Nucleophosmin-1 (NPM1+) * [HEMAML0028 28771]

• A Phase I Study of MEK Inhibitor MEK162 Combined with Idarubicin and Cytarabine Induction in Patients with Relapsed/Refractory RAS-Mutated Acute Myeloid Leukemia * [HEMAML0030 29150]

• A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy versus Salvage Chemotherapy in Subjects with FLT-ITD Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed after First-Line Treatment with or without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation * [HEMAML0032 30688]

• A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician’s Choice in Patients Greater Than or Equal to 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation SOPRA Study: Selinexor (KPT-330) in Older Patients with Relapsed AML * [HEMAML0033 31205]

• A Phase I Dose Escalation Study of Ibrutinib with Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia * [HEMAML0036 35003]

• A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD [COGAAML1031-BMT265 CIRB]

• A Phase III Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and a Phase II Study of Natural Killer Cell Transplantation in Patients with Newly Diagnosed Acute Myeloid Leukemia [PEDSAML08 15114]

• A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) * [SWOGS0919 25728]

• A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) * [SWOGS1203 CIRB]

**Chronic Lymphocytic Leukemia**

• A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy [HEMCLL0016 31325]
• A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion [HEMCLL0017 31534]

• A Phase 1, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia * [HEMCLL0018 31443]

• A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia * [HEMCLL0020]

• A Randomized Phase 3 Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (> 65 years of Age) with Chronic Lymphocytic Leukemia (CLL) * [SWOGA041202 CIRB]

• A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) * [SWOGE1912 CIRB]

• Detection of Serum Biomarkers for FDG-PET Positive Lung Nodules [LUN0045 19736]

• Phase II Trial of Individualized Lung Tumor Stereotactic Ablative Radiotherapy (SABR) [LUN0048 22476]

• A Randomized Phase II Study Comparing Concise (3 months) versus Prolonged (2 years) Afatinib as Adjuvant Therapy for Patients with Resected Stage I-II NSCLC with EGFR Mutation [LUN0058 27192]

• An Integrated Research Program for the Lung Stanford Nodule Assessment Program (Lung-SNAP) [LUN0060 27791]

• A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors [LUN0063 29900]

• A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) [LUN0066 31236]

• A Phase II Study of Erinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC) [LUN0067 30982]

• TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy [LUN0069 34310]

• Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-Small Cell Lung Cancer * [LUN0071 34863]

LUNG & RESPIRATORY TRACT

• Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients [LUN0017 4086]

• Novel CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy * [LUN0034 15582]

• Pulmonary Interstitial Lymphography in Early Stage Lung Cancer * [LUN0040 18395]

CONTACT

• Cancer Stanford: (650) 498-7061

• Zhou

• Gable

• San Pedro-Salcedo

• Nair

• Gable

• San Pedro-Salcedo

• Zhou

• Nair

• San Pedro-Salcedo
<table>
<thead>
<tr>
<th>Study</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Pivotal Multi-Center, Randomized, Single-Blinded Study Comparing the A Pivotal Multi-Center, Randomized, Controlled, Single-Blinded Study Comparing the Silver Nitrate-Coated Indwelling Pleural Catheter (SNCIPC) to the Uncoated PleurX® Pleural Catheter for the Management of Symptomatic, Recurrent, Malignant Pleural Effusions for the Management of Symptomatic, Recurrent, Malignant Pleural Effusions * [LUN0073]</td>
<td>Zhou</td>
</tr>
<tr>
<td>A Phase II, Multi-Center, Open-Label, Five-Arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges * [METS0002 33981]</td>
<td>Quick</td>
</tr>
<tr>
<td>Molecular Analysis of Thoracic Malignancies [THOR0004 21319]</td>
<td>Zhou</td>
</tr>
<tr>
<td>Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) * [ECOGA081105 32832]</td>
<td>Dib</td>
</tr>
<tr>
<td>Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) [ECOGA151216 32719]</td>
<td>Dib</td>
</tr>
<tr>
<td>Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after First-Line Chemotherapy [ECOGC30901 28128]</td>
<td>Dib</td>
</tr>
<tr>
<td>A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harbor the Anaplastic Lymphoma Kinase (ALK) Fusion Protein * [ECOGE4512 32883]</td>
<td>Dib</td>
</tr>
<tr>
<td>Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (Screening Step) * [ECOGS1400 33171]</td>
<td>Dib</td>
</tr>
<tr>
<td>RTOG 0538/CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide [RTOG0538 15388]</td>
<td>Brown (Katie)</td>
</tr>
<tr>
<td>Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) [RTOG1106 25283]</td>
<td>Gable</td>
</tr>
<tr>
<td>A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) [RTOG1306 28013]</td>
<td>Brown (Katie)</td>
</tr>
</tbody>
</table>

**LYMPHOMA: HODGKIN'S**

<table>
<thead>
<tr>
<th>Study</th>
<th>Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase II Trial of Sequential SGN-35 Therapy with Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma [LYMHD0009 21327]</td>
<td>Hapanowicz</td>
</tr>
<tr>
<td>A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma [LYMHD0011 26015]</td>
<td>Hapanowicz</td>
</tr>
<tr>
<td>A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) * [LYMHD0013 34078]</td>
<td>Choudhury</td>
</tr>
<tr>
<td>A Phase 1/2 Trial Evaluating Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma after Failure of Frontline Therapy [LYMHD0014 34879]</td>
<td>Sabile</td>
</tr>
<tr>
<td>A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma [ECOGE4412 28715]</td>
<td>Plahn</td>
</tr>
<tr>
<td>Reduced Duration Stanford V Chemotherapy with or without Low-dose Tailored-field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma [PEDSHOD08 16880]</td>
<td>Falwell</td>
</tr>
<tr>
<td>A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND#11717) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma * [COGAHOD1221 CIRB]</td>
<td>Falwell</td>
</tr>
</tbody>
</table>
• Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma * [COGALTE11C1]

LYMPHOMA: NON-HODGKIN'S CONTACT

Follicular / Indolent B-Cell

Untreated
• Phase 1/2, Non-Randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination with Localized Low-Dose Radiation in Patients with Untreated Low-Grade B-cell Lymphoma [LYMNHL0120 31224]
• A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma [LYMNHL0126 33944]

Previously Treated
• A Phase I/Ii Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination with Local Radiation in Low-Grade B-cell Lymphomas [LYMNHL0119 31133]

Diffuse Large B-Cell

Untreated
• Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients * [COGANHL1131 CIRB]
• A Phase 2 Study of Brentuximab Vedotin in Combination with Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) as Front-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) [LYMNHL0112 27539]

Previously Treated
• Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B cell Lymphoma * [ECOGE1412 33014]

Mantle Cell

Untreated
• Phase I/Ii Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for Mantle Cell Lymphoma [LYMNHL0040-BMT212 5089]

Waldenström’s Macroglobulinemia
• A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination with Rituximab in Subjects with Previously Treated Waldenstrom’s Macroglobulinemia [LYMWA0009 30660]

Multiple Histologies

Previously Treated
• Rare and Cutaneous Non-Hodgkin Lymphoma Registry [COGANHL04B1 14301]
• A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study [LYM0006-EXT 26563]

Choudhury

• An Open-Label, Treatment-Option Protocol of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-Positive Cutaneous T-cell Lymphoma [LYMNHL0095-EXT 27566]

Rajasansi

• A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination with Rituximab in Subjects with Relapsed/Refractory B-Cell Malignancies * [LYMNHL0106 26820]

Okada

• A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Refractory or Relapsed Lymphoid Malignancies [LYMNHL0117 30607]

Choudhury

• A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas * [LYMNHL0129 33364]

McDonald/Okada

Peripheral T-Cell Lymphoma

• A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas: the ECHELON-2 Study [LYMNHL0100 26031]

Choudhury

Cutaneous T-Cell Lymphoma

• Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing [LYMNHL0091 21750]

Ungewickell

• A Randomized, Open-label, Phase 3 Trial of Brentuximab Vedotin (SGN-35) versus Physician’s Choice (Methotrexate or Bexarotene) in Patients with CD30-Positive Cutaneous T-Cell Lymphoma [LYMNHL0095 23751]

Rajasansi

• Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma [LYMNHL0099 25169]

Rajasansi

• A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma * [LYMNHL0103 26192]

Rajasansi

• A Phase II Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome [LYMNHL0118 30739]

Rajasansi

• A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients with Stage IA, IB or IIA Cutaneous T-Cell Lymphoma [LYMNHL0121 31914]

Rajasansi

• A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma * [LYMNHL0124 33259]

Bruce

• A Randomized Phase I Dose-Escalation Trial of Carfilzomib with and without Romidepsin in Cutaneous T-Cell Lymphoma * [LYMNHL0127 28981]

Rajasansi

• Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL) * [LYMNHL0131 34884]

Rajasansi

• A Single Arm, Open-Label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of NM-IL-12 (rHuIL-12) in Patients with Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT) * [LYMNHL0133 35026]

Rajasansi

MELANOMA/OTHER SKIN CANCERS

• A Pilot Study of Ipilimumab in Subjects with Stage IV Melanoma Receiving Palliative Radiation Therapy [MEL0005 21970]

Shura/Di Bari

CONTACT

(650) 498-7061
• A Phase 1b, Open-label, Multicenter, Dose-escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma [METS0003 34637]

**Basal Cell Carcinoma**

• Double-Blind, Randomized, Placebo-Controlled Two-Period Crossover Study to Assess the Effect of L-Carnitine on Vismodegib-Associated Muscle Spasms [SKIN0018 27478]

• An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of LDE225 and BKM120 for the Treatment of Advanced Basal Cell Carcinomas [SKIN0020 29839]

• Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients with Advanced Basal Cell Carcinoma * [SKIN0028 30608]

• A Case Study of the Effects of Topical Itraconazole on Pharmacodynamic Modulation of Hedgehog Target Gene Expression in BCC in Patients * [SKIN0030 33132]

**Merkel Cell Carcinoma**

• A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC) [SKIN0025 31473]

**Multiple Myeloma**

• A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age [HEMMYLO021-BMT252 24899]

**Multiple Myeloma/Amyloidosis**

• A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis [HEM0024 24574]

**Myelodysplastic Syndrome (MDS)**

• Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies [HEM0026 25483]

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [HEM0041 31543]

• A Biologic Correlative Study for the "Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies [HEM0026-COR 27231]

**Myeloproliferative Disorders (MPD)**

• A Pilot Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis with or without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD) [HEMMPD0016 25727]

• A Phase 2, Open-Label, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), or Post-Essential Thrombocythemia MF (post-ET MF) * [HEMMPD0017 26823]

• A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) [HEMMPD0018 28848]
- Myeloproliferative Disorders-Research Consortium (MPD-RC) MPD-RC 112: Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia * [HEMMPD0019-TX 29750]
- A Phase II Study of Ibrutinib in Advanced Systemic Mastocytosis [HEMMPD0021 31815]
- Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR [HEMMPD0022 32369]
- A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis with Progressive or Relapsed Disease [HEMMPD0023 33137]
- A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis * [HEMMPD0024 33887]
- SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms * [HEMMPD0025 34643]
- A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor * [HEMMPD0026]

**NEUROBLASTOMA**

- Neuroblastoma Biology Studies [COGANBL0081 10993]
- Neuroblastoma Biology Protocol [NANT200405 23186]
- Phase I/I Study OF MLN8237 in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma [NANT200903 24996]

**PROSTATE**

- Quality of Life Following Radical Prostatectomy [PROS0012 13913]
- Real-Time MV/kV Image Guided Radiation Therapy * [PROS0038 18993]
- Transrectal Photoacoustic Imaging of the Prostate [PROS0044 21760]
- Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study [PROS0046 22701]
- A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Castration-resistant Prostate Cancer [PROS0047 30587]
- Feasibility of Using Trans-Perineal Clarity Autoscan Ultrasound Imaging for Prostate Motion Management, Tissue Characterization, and Treatment Monitoring * [PROS0055 27372]

**CONTACT**

- Daniels
- Falwell
- Haas
- Xing
- Pham
- Kothapalli/Sonn
- Shura
- Pradhan
• A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2 [PROS0058 29832]

• Prostate MRI and Fusion of MRI and Ultrasound Images to Improve Prostate Cancer Diagnosis and Treatment * [PROS0059 29873]

• Combined “One Stop Shop” NaF/FDG PET/MRI Evaluation of Response to Xofigo in mCRPC Patients [PROS0063 32653]

• A Randomized Open-Label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination with Abiraterone Acetate or Enzalutamide in Subjects with Castration-Resistant Prostate Cancer (CRPC) Who Have Bone Metastases * [PROS0064 32882]

• A Phase III Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer [PROS0065 32058]

• PCa003: A Feasibility Study to Evaluate the Safety and Preliminary Effectiveness of Focal MR-Guided Focused Ultrasound Treatment of Locally Confined Low and Intermediate Risk Prostate Cancer * [PROS0067 33120]

• 68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients with Prostate Cancer [PROS0068 32985]

• 68Ga-RM2 PET/MRI in the Evaluation of Patients with Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans * [PROS0074 35155]

• Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radio Therapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial * [RTOG0924 CIRB]

QUALITY OF LIFE

Gastroesophageal
• The Gastric Cancer Foundation: A Gastric Cancer Registry [GI0005 20285]

Liver
• An Investigational Plan Evaluating the Operative Management of Parenchymal Bleeding by Means of an Adjunctive Application of BioFoam® Surgical Matrix in Liver Surgery * [HEP0029 17480]

Prostate
• Quality of Life Following Radical Prostatectomy [PROS0012 13913]

QUALITY OF LIFE/CANCER SURVIVORSHIP

Anal/Colon & Rectum
• Vaginal Quality of Life and Functional Outcomes after Combined Modality Therapy of Chemotherapy and Intensive Modulated Radiation Therapy (IMRT) for Rectal and Anal Cancer Patients [REC0005 17711]

SARCOMA

• A COG Study for Collecting and Banking Ewing Sarcoma Specimens [COGAEWS0781 13014]

• Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma [COGAEWS1031 19999]

• Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma * [COGAEWS1221 CIRB]
• Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IN# 118613) * [COGARST1321 CIRB]

• A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol [COGD9902 9586]

• A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens [COGAOST06B1 13013]

• A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy [SARCOMA0013 29884]

• A Phase II Study of Hypofractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites * [SARCOMA0014 27039]

• Pilot Study to Explore the Role of Circulating Tumor DNA in the Management of Patients with Soft Tissue Sarcoma [SARCOMA0016 31596]

• PLX108-10: A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath [SARCOMA0018 33236]

• A Phase 1/2 Study of FPA008, an Anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT) * [SARCOMA0019 34269]

• A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (nab-rapamycin) in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa) * [SARCOMA0020 34630]

• A Phase 1B Dose-Escalation and Phase 2A Study of TRC105 in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma * [SARCOMA0021 35121]

• A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 * [SARCOMA0022 35660]

• A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-Like Sarcomas [SARC-024 30489]

**UROTHELIAL**

• A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer [ECOGS1011 24817]
Protocols to open soon

New trials are continually added to this list. Please call the Cancer Clinical Trials Office or visit our website for updates.

Phone: 650-498-7061

Ofrecemos asistencia en español acerca de estudios clínicos de cáncer: (650) 724-3155

cancer.stanford.edu/trials

For information about Clinical trials for children with cancer
Please contact the Lucile Packard Children’s Hospital Hematology/Oncology New Patient Coordinator
Phone: 650-725-1072

stanfordchildrens.org/en/service/oncology

For information about Cancer Prevention Institute of California (CPIC) studies
Please contact
Phone: 510-608-5000

cpic.org